Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Oral gildeuretinol demonstrated a clinically meaningful reduction in the GA lesion growth rate at 24 months in the SAGA study. BI 771716, with technology licensed from CDR-Life, is a highly specific ...

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space At this year's EURETINA Congress, we caught up with Enrico Borrelli, MD, FEBO, during a break from his busy schedule. He is ...

AG-73305 is bi-specific, with anti-VEGF and anti-integrin. The dual mechanism of action has provided some interesting results.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated ...

It is not every day that a paper about treating eye disease appears in The Lancet. 1 The article by Campochiaro et al1 on a clinical trial of gene therapy speaks to the potential impact of this ...

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina ...

A recent study reported that proven early-onset sepsis is an early risk factor for severe retinopathy of prematurity (ROP), 1 according to first author Salma El Emrani, BSc, who is from the Department ...

TIME Magazine named Zack Dvey-Aharon, PhD, to the 2024 TIME100 AI list. This annual list highlights the 100 most influential individuals in artificial intelligence (AI). According to a press release 1 ...

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1. Priovant Therapeutics has enrolled the first patients in the CLARITY Phase 3 study evaluating brepocitinib in ...

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.